India, May 14 -- The pharmaceutical consulting business BRS Analytical Services announced a countrywide recall of about 76,000 eye drop cases, as per FDA enforcement complaint.

According to AvKare, a medical firm that first notified the recall, the urgent recall comes after an FDA audit discovered many cGMP discrepancies, which are alterations from the regular manufacturing method used during pharmaceutical production.

The FDA also recalled the drops, which were intended to soothe dry, itchy eyes, because of a "lack of assurance of sterility."

While the eye drops' present threat to health is unknown, potential hazards cannot be completely ruled out, according to AvKare.

Customers have been advised to immediately stop use of the impact...